Aktuellt
SENASTE
Sprint Bioscience’s Q2 20 was marked by the company completing its rights issue for SEK48.5m (SEK40.6m net of transaction-related costs). With an estimated net cash position of c.SEK32m going into H2, we believe Sprint Bioscience has enough cash in the bank to cover operating expenses for another year, without the worry of having to raise additional funds, and it has the optionality of reaching a new licensing deal.
LÄS MER
